Last updated: 17 February 2022 at 6:15pm EST

Martin Sutter Net Worth




The estimated Net Worth of Martin P Sutter is at least $85.6 Million dollars as of 17 February 2022. Mr. Sutter owns over 4,000 units of Abiomed stock worth over $49,681,198 and over the last 21 years he sold ABMD stock worth over $35,647,205. In addition, he makes $267,496 as Independent Director at Abiomed.

Mr. Sutter ABMD stock SEC Form 4 insiders trading

Martin has made over 16 trades of the Abiomed stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 4,000 units of ABMD stock worth $1,258,840 on 17 February 2022.

The largest trade he's ever made was exercising 37,000 units of Abiomed stock on 8 May 2018 worth over $571,280. On average, Martin trades about 2,073 units every 56 days since 2003. As of 17 February 2022 he still owns at least 130,390 units of Abiomed stock.

You can see the complete history of Mr. Sutter stock trades at the bottom of the page.





Martin Sutter biography

Martin P. Sutter serves as Independent Director of the Company. Mr. Sutter has been the Co-Founder and a Managing Director of EW Healthcare Partners, previously known as Essex Woodlands Health Ventures, a healthcare-focused growth equity firm. Educated in chemical engineering and finance, Mr. Sutter has more than 35 years of management experience in operations, marketing, finance and venture capital. Mr. Sutter holds a Bachelor of Science degree from Louisiana State University and a Master of Business Administration from the University of Houston.

What is the salary of Martin Sutter?

As the Independent Director of Abiomed, the total compensation of Martin Sutter at Abiomed is $267,496. There are 12 executives at Abiomed getting paid more, with Michael Minogue having the highest compensation of $16,612,800.



How old is Martin Sutter?

Martin Sutter is 65, he's been the Independent Director of Abiomed since 2008. There are 4 older and 13 younger executives at Abiomed. The oldest executive at Abiomed Inc. is Jeannine Rivet, 72, who is the Independent Director.

What's Martin Sutter's mailing address?

Martin's mailing address filed with the SEC is 22 Cherry Hill Dr, Beverly, MA 01915, USA.

Insiders trading at Abiomed

Over the last 21 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose, and David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.



What does Abiomed do?

Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.



Complete history of Mr. Sutter stock trades at Abiomed, CTI BioPharma Corp, and La Jolla Pharmaceutical Co

Insider
Trans.
Transaction
Total value
Martin P Sutter
Director
Sale $1,258,840
17 Feb 2022
Martin P Sutter
Director
Sale $617,320
16 Feb 2022
Martin P Sutter
Director
Sale $607,300
15 Feb 2022
Martin P Sutter
Director
Sale $7,691,850
16 Nov 2021
Martin P Sutter
Director
Sale $2,473,650
17 Aug 2021
Martin P Sutter
Director
Sale $2,003,100
18 May 2021
Martin P Sutter
Director
Sale $2,417,550
16 Feb 2021
Martin P Sutter
Director
Sale $403,410
17 Nov 2020
Martin P Sutter
Director
Sale $468,285
18 Aug 2020
Martin P Sutter
Director
Option $119,880
4 May 2020
Martin P Sutter
Director
Option $92,040
8 May 2019
Martin P Sutter
Director
Sale $7,203,200
13 Feb 2019
Martin P Sutter
Director
Sale $10,502,700
4 Feb 2019
Martin P Sutter
Director
Option $571,280
8 May 2018
Martin P Sutter
Director
Buy $451,275
29 May 2015
Martin P Sutter
Director
Buy $138,800
27 May 2008


Abiomed executives and stock owners

Abiomed executives and other stock owners filed with the SEC include: